medigraphic.com
ISSN 1727-897X (Electronic)

2020, Number 3

<< Back Next >>

Medisur 2020; 18 (3)

Economic burden of pneumococcal disease in preschoolers in the

Marrero AM, García FA, Gálvez GAM

Language: Spanish
References: 21
Page: 322-332
PDF size: 589.80 Kb.


ABSTRACT

Foundation: calculating the economic burden of pneumococcal disease care and treatment in preschoolers in the primary health level in Cuba, helps to base the allocation of resources and visualize the need to find ways to prevent the disease.
Objective: to estimate the economic burden of pneumococcal disease in preschoolers in the Cecilio Ruiz de Zárate Castellón Teaching Polyclinic, in Cienfuegos.
Methods: a study of the modeled disease cost was carried out, from the institutional perspective; time horizon was defined as the time between diagnosis and medical discharge.
Results: direct medical cost of patients under five years old, with pneumonia, treated only at the first level of health, has an average value of 237 Cuban pesos; in patients with acute otitis media it was 120 CUP. Those attended at the primary level after a hospital discharge had an average direct medical cost of between 106.96 CUP; in cases with acute otitis media, it was 89.83 CUP and for those who discharged after meningitis or sepsis, it was 152.63 CUP with the highest average, minimum and maximum cost value due to the extension of post-discharge care. Within the processes, home visits cause the greatest expense and, of the items, salary. Pneumococcal disease represented an economic burden of more than 15 400 00 CUP.
Conclusions: Pneumococcal disease care for the Cecilio Ruiz de Zárate Castellón Polyclinic is expensive. These estimates should be taken into account by those who make decisions to introduce pneumococcal vaccination in the Cuban child population.


REFERENCES

  1. Valenzuela MT, O’Loughlin R, De La Hoz F, Gomez F, Constenla D, Sinha A, et al. The burden of pneumococcal disease among Latin American and Caribbean children: review of the evidence. Rev Panam Salud Pública. 2009;25(3):270-9.

  2. Mokdad AH, Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, et al. Estimates of the global, regional, and national morbidity, mortality, and etiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infec Dis. 2017;17(11):1133-61.

  3. Billings ME, Deloria-Knoll M, O’Brien K. Global Burden of Neonatal Invasive Pneumococcal Disease: A Systematic Review and Meta-analysis. Pediatric Infect Dis J. 2016;35(2):72-179.

  4. Valenzuela ME, Flannery B. La epidemiología neumocócica global. En: Organización Panamericana de la Salud. Acta del Segundo Simposio Regional sobre Neumococo. Procedente del II Simposio Regional de Enfermedad Neumocócica. Sao Paulo, Brasil. Geneva: OPS; 2006. p. 4-8.

  5. Sociedad Española de QuimioterapiaInfección neumocócica. por neumococo un problema global. STAFF. 2015;III(17):3-15.

  6. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valentpneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. Morb Mortal Wkly Rep. 2005;54:893-7.

  7. Barraza-Lloréns M, Guajardo-Barrón V, Picó J, García R, Hernández C, Mora F, et al. Carga económica de la diabetes mellitus en México, 2013 [Internet]. México, D.F.: Funsalud; 2015 [citado 03/04/2018]. Disponible en: Disponible en: http://funsalud.org.mx/portal/wp-content/uploads/2015/08/Carga-Economica-Diabetes-en-Mexico-2013.pdf.

  8. Peña Kieninger M, Giménez Caballero E, Arbo Sosa A, Torres Amarilla C, Jáuregui B, Bess Janus C, et al. Cost-efectiveness analysis of neumococacal conjúgate vaccine introduction in Paraguay. Vaccine. 2015;33:A143-A153.

  9. Mezones-Holguin E, Canelo-Aybara C, Clarkc AD, Bess Januszd C, Jaúreguid B, Escobedo-Palzaa S, et al. Cost-effectiveness analysis of 10-and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine . 2015;33:A154-A166.

  10. Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia. Cost Eff Resour Alloc. 2015;13:6.

  11. Linares Pérez N, Toledo Tomaní ME, Valdez Balbin Y. La vigilancia y la evaluación de impacto como estrategias de salud pública: aportes para la introducción de la nueva vacuna cubana contra Streptococcus pneumoniae. Vacunas. 2018;19(2):44-51.

  12. Cuba. Ministerio de Salud Pública. Programa del Médico y Enfermera de la Familia. La Habana: Editorial Ciencias Médicas; 2011.

  13. Departamento Nacional de Salud Materno Infantil. Programa Nacional de Atención Materno Infantil. La Habana: MINSAP; 1989.

  14. García Ruiz AJ, Leiva Fernández F, Martos Crespo F. Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol. Arch Bronconeumonol. 2005;41(5):242-8.

  15. Linares Pérez N, Toledo ME, Santana D, García A, García D, Valdés Y, Vérez V. From individual to herd protection with pneumococcal vaccines: the contribution of the Cuban pneumococcal conjugate vaccine implementation strategy. Int J Infect Dis. 2017;60:98-102.

  16. Morano R, Pérez F, Brosa M, Pérez Escolano I. Análisis de coste-efectividad de la vacunación antineumocócica en España. Gac Sanit. 2011;25(4):267-273.

  17. Gómez JA, Tirado JC, Rojas AA, Alba MM, Topachevskyi O. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. BMC Public Health. 2013;13(1):1025-37.

  18. Marrero M, García A. Bases conceptuales y metodológicas para estimar el costo de las enfermedades neumocócicas en niños en el primer nivel de atención de salud. Rev Cubana Salud Pública [revista en Internet]. 2018 [citado 18/03/2018];43(4):[aprox. 9p]. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662017000400009&lng=es.

  19. Fernández García A, Gálvez González AM, Castillo Guzmán A. Costo institucional del infarto agudo del miocardio en el Instituto de Cardiología y Cirugía Cardiovascular. Rev Cubana Salud Pública [revista en Internet]. 2008 [citado 27/11/2017];34(4):[aprox. 9p]. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662008000400006&lng=es.

  20. Barroso Utra IM, García Fariñas A, Rodríguez Salvá A, de Vos P, Bonet Gorbea M, Van Der Stuyft P. El ingreso en el hogar y su costo directo en Cuba. Rev Panam Salud Pública . 2007;21(2/3):85-95.

  21. Sabin Vaccine Institute. Carga de enfermedad neumocócica en América Latina y el Caribe. Análisis de la evidencia [Internet]. Washington: Sabin Vaccine Institute; 2016 [citado 22/03/2018]. Disponible en: Disponible en: https://www.sabin.org/sites/sabin.org/files/marite_1.pdf.




2020     |     www.medigraphic.com